M Jane Black Selected Research

PD 123319

1/2012	Influence of Angiotensin II Subtype 2 Receptor (AT(2)R) Antagonist, PD123319, on Cardiovascular Remodelling of Aged Spontaneously Hypertensive Rats during Chronic Angiotensin II Subtype 1 Receptor (AT(1)R) Blockade.
12/2005	The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.
11/2004	Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Jane Black Research Topics

Disease

5	Fibrosis (Cirrhosis) 10/2012 - 11/2004
4	Premature Birth (Birth, Premature) 08/2021 - 12/2009
3	Birth Weight (Birth Weights) 01/2021 - 12/2002
3	Hypertrophy 01/2012 - 11/2004
3	Atherosclerosis 02/2006 - 08/2003
2	Inflammation (Inflammations) 03/2022 - 04/2013
2	Fetal Growth Retardation (Intrauterine Growth Retardation) 12/2014 - 09/2014
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2014 - 08/2003
2	Chorioamnionitis 09/2014 - 01/2013
2	Hypertension (High Blood Pressure) 09/2014 - 01/2004
2	Body Weight (Weight, Body) 03/2010 - 12/2009
1	Albuminuria 01/2021
1	Vascular System Injuries 01/2020
1	Disease Progression 01/2017
1	fetal inflammatory response syndrome 01/2013
1	Vasculitis (Vasculitides) 01/2013
1	Hyperglycemia 10/2012
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2012
1	Fetal Alcohol Spectrum Disorders 08/2012
1	Hemorrhage 08/2012
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 08/2012
1	Polyploidy 08/2010
1	Atherosclerotic Plaque (Atheroma) 01/2008
1	Hyperplasia 02/2006
1	Cardiomegaly (Heart Hypertrophy) 11/2004
1	Neointima 08/2003

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 12/2014 - 01/2004
4	CholesterolIBA 04/2006 - 08/2003
4	Methionine (L-Methionine)FDA Link 04/2006 - 08/2003
3	neodymium pyrocatechin disulfonate (NPD)IBA 01/2021 - 12/2002
3	PD 123319IBA 01/2012 - 11/2004
2	LipopolysaccharidesIBA 03/2022 - 04/2013
2	GlucocorticoidsIBA 08/2021 - 12/2009
2	Messenger RNA (mRNA)IBA 01/2020 - 08/2012
2	SteroidsIBA 09/2014 - 12/2009
2	CytokinesIBA 01/2013 - 08/2012
2	candesartan cilexetil (Amias)FDA Link 01/2012 - 11/2004
2	DNA (Deoxyribonucleic Acid)IBA 08/2010 - 12/2005
2	Dietary CholesterolIBA 04/2006 - 08/2003
2	HomocysteineIBA 04/2006 - 08/2003
2	Type 2 Angiotensin ReceptorIBA 02/2006 - 12/2005
1	P-SelectinIBA 01/2020
1	Betamethasone (Celestone)FDA Link 01/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2017
1	Retinaldehyde (Retinal)IBA 01/2013
1	Blood Glucose (Blood Sugar)IBA 10/2012
1	CollagenIBA 10/2012
1	Phospholipids (Phosphatides)FDA LinkGeneric 08/2012
1	Ethanol (Ethyl Alcohol)IBA 08/2012
1	Surface-Active Agents (Surfactants)IBA 08/2012
1	AngiotensinsIBA 01/2008
1	ReninIBA 01/2008
1	Lewis X AntigenIBA 01/2008
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2008
1	Angiotensin-Converting Enzyme 2IBA 02/2006
1	LigandsIBA 12/2005
1	Mitogen-Activated Protein KinasesIBA 12/2005
1	Type 1 Angiotensin ReceptorIBA 12/2005
1	CGP 42112AIBA 12/2005
1	SaltsIBA 01/2004

Therapy/Procedure

1	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 04/2013